KABRO, ANZHELIKA;LUND, KATE-LYN;MARINEAU, JASON J.;ROY, STEPHANIE; ROBERT;CIBLAT, STEPHANE;SCHMIDT, DARBY;WINTER, DANA K.;PIRAS, HENRI;MALOJCIC, GORAN;CHUAQUI, CLAUDIO;ZAHLER;WHITMORE, KENNETH MATTHEW;ZAHLER, ROBERT
发明人:
ZAHLER, ROBERT,MARINEAU, JASON J.,CIBLAT, STEPHANE,WINTER, DANA K.,KABRO, ANZHELIKA,ROY, STEPHANIE,SCHMIDT, DARBY,CHUAQUI, CLAUDIO,MALOJCIC, GORAN,PIRAS, HENRI,WHITMORE, KENNETH MATTHEW,LUND, KATE-LYN
申请号：
CA3030795
公开号：
CA3030795A1
申请日:
2017.07.13
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
